ATE545866T1 - Liganden von g-protein-gekoppelten rezeptoren und verfahren - Google Patents

Liganden von g-protein-gekoppelten rezeptoren und verfahren

Info

Publication number
ATE545866T1
ATE545866T1 AT03718335T AT03718335T ATE545866T1 AT E545866 T1 ATE545866 T1 AT E545866T1 AT 03718335 T AT03718335 T AT 03718335T AT 03718335 T AT03718335 T AT 03718335T AT E545866 T1 ATE545866 T1 AT E545866T1
Authority
AT
Austria
Prior art keywords
methods
protein
ligands
coupled receptors
relates
Prior art date
Application number
AT03718335T
Other languages
German (de)
English (en)
Inventor
Ying Jiang
Fang Zhang
Nicholas Murgolo
Lin Luo
Jason Simon
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE545866T1 publication Critical patent/ATE545866T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
AT03718335T 2002-04-12 2003-04-10 Liganden von g-protein-gekoppelten rezeptoren und verfahren ATE545866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37264002P 2002-04-12 2002-04-12
PCT/US2003/011159 WO2003087134A2 (en) 2002-04-12 2003-04-10 G-protein coupled receptor ligands and methods

Publications (1)

Publication Number Publication Date
ATE545866T1 true ATE545866T1 (de) 2012-03-15

Family

ID=29250884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718335T ATE545866T1 (de) 2002-04-12 2003-04-10 Liganden von g-protein-gekoppelten rezeptoren und verfahren

Country Status (9)

Country Link
US (3) US7338772B2 (https=)
EP (1) EP1532446B1 (https=)
JP (4) JP4594623B2 (https=)
CN (1) CN1324047C (https=)
AT (1) ATE545866T1 (https=)
AU (1) AU2003221878A1 (https=)
CA (1) CA2481508A1 (https=)
MX (1) MXPA04009959A (https=)
WO (1) WO2003087134A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2481508A1 (en) 2002-04-12 2003-10-23 Schering Corporation G-protein coupled receptor ligands and methods
WO2006039256A1 (en) * 2004-09-29 2006-04-13 Glaxo Group Limited Use of gpr103 agonists for modulating feeding behaviour
WO2009043524A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as therapeutic agent
JP5313068B2 (ja) * 2009-03-09 2013-10-09 富士フイルム株式会社 側視内視鏡装置
WO2016058094A1 (en) * 2014-10-14 2016-04-21 Université de Montréal BIOSENSOR BASED ON GβΥ-INTERACTING PROTEINS TO MONITOR G-PROTEIN ACTIVATION
JP6405352B2 (ja) * 2016-09-16 2018-10-17 株式会社Ｓｕｂａｒｕ 直噴内燃機関のピストン

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CN1167490A (zh) * 1994-11-10 1997-12-10 人体基因组科学有限公司 人司登尼亚钙蛋白-α
DE69733649T2 (de) 1996-04-09 2006-05-18 NPS Pharmaceuticals, Inc., Salt Lake City Calcylitische verbindungen
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
AU5784799A (en) 1998-08-24 2000-03-14 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
CA2348688A1 (en) 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
WO2000031256A1 (fr) 1998-11-20 2000-06-02 Chugai Research Institute For Molecular Medicine, Inc. Nouveau gene codant une proteine membranaire specifique au cerveau
KR20080104062A (ko) 1998-11-20 2008-11-28 아레나 파마슈티칼스, 인크. 사람의 오르판 ｇ 단백질 커플링 수용체
IL145894A0 (en) 1999-04-29 2002-07-25 Novo Nordisk As Use of heparin-binding antagonists in the inhibition of bradykinin release
WO2000078809A1 (en) 1999-06-21 2000-12-28 Smithkline Beecham Corporation Axor16, a g protein coupled receptor
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
AU6727900A (en) 1999-08-27 2001-03-26 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
AU7645700A (en) * 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
WO2001048189A1 (fr) 1999-12-28 2001-07-05 Helix Research Institute Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers
AU2001271838A1 (en) * 2000-07-06 2002-01-21 Bayer Corporation Human neuropeptide y-like g protein-coupled receptor
WO2003020932A1 (en) * 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. Novel secretory proteins and dna thereof
CA2481508A1 (en) 2002-04-12 2003-10-23 Schering Corporation G-protein coupled receptor ligands and methods

Also Published As

Publication number Publication date
EP1532446A4 (en) 2006-06-07
JP2010279373A (ja) 2010-12-16
JP2006254916A (ja) 2006-09-28
MXPA04009959A (es) 2004-12-13
US20080138348A1 (en) 2008-06-12
WO2003087134A2 (en) 2003-10-23
JP2005528894A (ja) 2005-09-29
US7338772B2 (en) 2008-03-04
AU2003221878A8 (en) 2003-10-27
JP5284313B2 (ja) 2013-09-11
CA2481508A1 (en) 2003-10-23
JP2010252805A (ja) 2010-11-11
CN1659438A (zh) 2005-08-24
WO2003087134A3 (en) 2005-03-24
AU2003221878A1 (en) 2003-10-27
US8133980B2 (en) 2012-03-13
EP1532446A2 (en) 2005-05-25
US7807390B2 (en) 2010-10-05
US20030223992A1 (en) 2003-12-04
CN1324047C (zh) 2007-07-04
JP4594623B2 (ja) 2010-12-08
US20110020354A1 (en) 2011-01-27
EP1532446B1 (en) 2012-02-15

Similar Documents

Publication Publication Date Title
ATE439861T1 (de) Verfahren zur modulierung von cd200-rezeptoren
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
BR0314192A (pt) Antagonistas de receptores de mglu para tratamento de distúrbios associados com receptores de mglu incluindo vìcio e depressão
BR9710988A (pt) Método e compostos moduladores receptores de androgênio
BR0315167A (pt) Métodos para tratar a da dor administrando-se um antagonista do fator de crescimento de nervos e um analgésico opióide e composições contendo os mesmos
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE315230T1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
ATE400653T1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
DE60207254D1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
WO2002024222A3 (en) Ligands for g protein coupled receptors and methods of using them
MY150210A (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
ATE545866T1 (de) Liganden von g-protein-gekoppelten rezeptoren und verfahren
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
ATE393781T1 (de) Somatostatin analoge, deren radiomarkierte derivate und deren verwendung
HRP20041014B1 (hr) Novi spojevi kao modulatori opioidnog receptora
NO20065768L (no) Karbonsamid-opioidforbindelser
WO2002018941A3 (en) Screen for glutamate reuptake inhibitors, stimulators, and modulators
ATE504600T1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
EA200700951A1 (ru) БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
ATE230263T1 (de) At1 rezeptor antagonist zur anregung von apoptosis
AU2003211040A1 (en) The eaat2 promoter and uses thereof
WO2005038006A3 (en) Chimeric metabotropic glutamate receptors and uses thereof
DE602004019451D1 (de) Verwendung von löslichem T-Cadherin zur Behandlung von Stoffwechselkrankheiten